Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
about
The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disordersSwitching antipsychotic therapies.A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy'Why getting fat, Doc?' Weight gain and psychotropic medications.Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.Weight gain, obesity, and psychotropic prescribing.Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management.acp Best Practice No 168. The investigation and management of obesityIn vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophreniaChildren with special health care needs: acknowledging the dilemma of difference in policy responses to obesity.Emerging drugs in migraine treatment.Preventive treatment of migraine: effect on weight.Obesity: pathophysiology and treatment.What does the epidemic of childhood obesity mean for children with special health care needs?Lamivudine-Induced Liver Injury.Overweight and obesity among children with developmental disabilities.Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.The Investigation of Insulin Resistance in Two Groups of Epileptic Patients Treated with Sodium Valproate and Carbamazepine.Obesity and psychotropics.Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.Carbamazepine directly inhibits adipocyte differentiation through activation of the ERK 1/2 pathway.Prevalence and potential factors associated with overweight and obesity status in adults with intellectual developmental disorders.Propagation of adipogenic signals through an epigenomic transition state.Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complexExploring the benefits of an exercise program for people with schizophrenia: a qualitative study.Modification in body weight associated with antiepileptic drugs.Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial.Weight change in monozygotic twins treated with valproate.Naturalistic impact of second-generation antipsychotics on weight gain.Dietary fructose-related adiposity and glucocorticoid receptor function in visceral adipose tissue of female rats.Sex Differences in the Effects of Inhaled Corticosteroids on Weight Gain among Patients with Asthma
P2860
Q33600231-60B2D821-F0B1-4F41-A238-7FCA9A8D4F4EQ33838916-D7C5CB8E-EF1A-48E4-8BD8-8D10A8D7FC41Q33884174-9DD18766-E2C9-4F4F-A44C-3C4E20E61F42Q34299393-6CB9BDAD-78A0-482E-AF96-87042F2A062EQ34314781-B73337F3-FBD7-4FEE-A4CA-DFD6A5BED2F7Q34557537-691DA971-7E2F-4FB9-8FB8-C138C752AC72Q34745041-DC1A620A-52E5-4E4B-829E-410D1C94085FQ35033497-6D72EBDA-B67B-46FC-9623-2AF4D17E4009Q35069463-6BA28287-3424-4620-89E9-4C4803BC561DQ35235190-55DB54E2-7B05-4D9D-B66A-6C8111A0D308Q35602660-DF99CAC2-ECA6-476D-BD93-C3AA833C7EBAQ35987931-9507789B-BBF9-42A5-870A-7F6EB91FC70DQ36226380-D5EF33E9-FBF4-4D6A-889F-0F24C7D92A7DQ36651127-A5E0A76B-8DC6-4C11-9CB7-8E59F78F318CQ36929406-27FA9B70-C7C7-49BA-91ED-74D7B4FE6A33Q37094710-094DB3A3-A48D-42D4-850D-38C5C2F234A8Q37171035-95DA289C-9431-4AA7-A5AD-C1B313963A35Q37713560-D1137751-2869-40C1-81E0-9001BB2572D7Q37954390-983E056F-38CE-4770-B4AB-39E17CAF3C82Q37958894-59CBAAB7-FD45-4EC3-8FA6-EFC7E39D3B63Q39298349-DBD947A4-A972-425D-9659-130B782CA899Q39329839-B45A01FB-C402-4674-A2B7-BA1AC61E9959Q39703018-B5F0621D-B96E-43A8-B0CD-53F55D7239F9Q39756473-53DA77D4-0B6D-4CBA-A37F-E5D134BFAC1BQ40405319-6E613979-D50E-43F6-941B-65844A450699Q43065224-F0BE6EDB-4328-4B03-B86F-71B4A350FFF0Q44043948-F139F178-8571-482D-8204-72873231629DQ44402308-3CFFE7D9-9633-430C-872A-8B99D072A776Q46675935-386DD4E6-EB43-488C-B0F7-72DAEB77EA2EQ47344131-AAB065B6-4DFD-46C6-953D-46C016DFD8C6Q51168667-B21E1E73-9C3C-43AC-ADD4-BF296B6A3305Q58689843-E3D17ED8-A229-499C-B351-3E97EB313113
P2860
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
@en
type
label
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
@en
prefLabel
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
@en
P1433
P1476
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.
@en
P2093
P304
P356
10.2165/00002018-199614050-00005
P577
1996-05-01T00:00:00Z
P6179
1010171945